Such collaborations may take different forms: delivering novel monoclonal antibodies or other biologics to their intracellular target; improving the biodistribution of novel small molecules with ...

Insilico then applied its generative chemistry platform for drug discovery, Chemistry42, to the chosen novel intracellular target. The platform uses generative and scoring engines to come up with ...

A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.

On Wednesday, Goldman Sachs updated its outlook on shares of Intra-Cellular Therapies (NASDAQ:ITCI), raising the price target to $79 from $74 while maintaining a Neutral rating. The company's ...

Canaccord raised the firm’s price target on Intra-Cellular (ITCI) to $119 from $113 and keeps a Buy rating on the shares. The firm said they are encouraged by continued solid execution and ...

On Wednesday, Goldman Sachs (NYSE:GS) updated its outlook on shares of Intra-Cellular Therapies (NASDAQ:ITCI), raising the price target to $79 from $74 while maintaining a Neutral rating. The ...

Natural killer (NK) cells play an important role in the innate immune response to cancer and viral infections, and their ...

A number of research firms recently weighed in on ITCI. UBS Group dropped their target price on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a ...

A total of 12 analyst ratings have been received for Intra-Cellular Therapies, with the consensus rating being Outperform. The average one-year price target stands at $102.08, suggesting a ...

Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subi style="display:none;"ion plan is required to access premium news articles.

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in ...